News

Implanting electrodes into the brain triggers inflammation by activating a group of immune signaling proteins called the inflammasome — which detects infection and, in turn, prompts a strong inflammatory response, a new study shows. These findings may open new avenues to improve deep brain stimulation, a type of therapy used…

Sinopia Biosciences has selected SB-0110 as its lead clinical candidate for Parkinson’s disease after extensive preclinical studies. The move has triggered a cumulative funding of $3.3 million of its fast-track Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke. The fast-track SBIR…

The first healthy volunteer has been dosed in a clinical study that will test the safety and efficacy of Herantis Pharma’s HER-096 treatment candidate for Parkinson’s disease, the company announced in a press release. The Phase 1a clinical trial also is evaluating the ability of HER-096 to penetrate…

Medications to prevent nausea and vomiting usually are not necessary for Parkinson’s disease patients beginning treatment with Kynmobi (apomorphine hydrochloride), according to a recent analysis of Phase 3 clinical trial data. Nearly 90% of patients who did not use these medications were still able to achieve an optimal…

Measuring the length and density of nerves in the cornea — the clear outer layer of the eyeball — can help distinguish between motor subtypes of Parkinson’s disease, a new study suggests. The study, “The severity of corneal nerve loss differentiates motor subtypes in patients with…

Greater proportions of immune regulatory B-cells were associated with better motor performance in people with early Parkinson’s disease, a study revealed. Regulatory B-cell subsets may be protective by limiting pro-inflammatory responses that contribute to disease progression, data showed. Meanwhile, elevated levels of antibodies produced by regular B-cells against the…

Remote assessments using smartphones and smartwatches could be used in clinical trials to track the severity of Parkinson’s disease, a new study indicates. “In this multicenter study, a commercially available smartwatch and a smartphone research application captured key motor and non-motor features of early, untreated” Parkinson’s, the researchers wrote,…

Changes in the electrical activity of a brain region called the left inferior frontal cortex (LIFC) may underlie certain speech difficulties in people with Parkinson’s disease, a study found. Patients with more severe articulation problems had higher frequency activity in the LIFC, and more limited communication between the LIFC…

A molecule associated with oxidative stress, called allantoin, is found at higher levels in the blood of people with Parkinson’s disease relative to their peers without the neurodegenerative disorder, according to a new study. Allantoin and its ratio to uric acid (UA) — the antioxidant molecule from which it’s…

NeuroPoint Alliance’s (NPA) registry for people with Parkinson’s disease eligible for deep brain stimulation (DBS) surgery announced that it has completed its initial pilot phase, collecting information on more than 170 patients who underwent the treatment. Called the Registry for the Advancement of DBS in Parkinson’s Disease, or…